1st Quarter - Report

CHATMAN, LLC for THE LIVINGSTON GROUP FOR TITAN PHARMACEUTICALS

Period 1st Quarter 2019 Filed Apr 14, 2019 Signed by Priscilla A Chatman

Official filing
Firm
CHATMAN, LLC
Client
THE LIVINGSTON GROUP FOR TITAN PHARMACEUTICALS
Income
$10,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Encourage federal agencies to utilize Medication Assisted Treatment (MAT) for the treatment of opioid addiction. Work for a FDA label change for probuphine.

LobbyistCovered position, as disclosed
PRISCILLA CHATMAN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Work for FDA label change

LobbyistCovered position, as disclosed
PRISCILLA CHATMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.